¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"mixed melting point"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mixed vaccine
    È¥ÇÕ¹é½Å
  • acupuncture point
    °æÇ÷Á¡
  • blind point
    ¸ÍÁ¡
  • boiling point
    ²ú´ÂÁ¡, ºñµîÁ¡
  • conjugate point
    1. ÄÓ·¹Á¡ 2. °áÇÕÁ¡
  • corresponding point
    ´ëÀÀÁ¡
  • craniometric point
    ¸Ó¸®°èÃøÁ¡, µÎ°³°èÃøÁ¡
  • critical point
    ÀÓ°èÁ¡
  • cardinal point
    ±âº»Á¡
  • cut-off point
    °áÁ¤Á¡
  • dew point determination apparatus
    ³ëÁ¡°è
  • disparate point
    ºñ´ëÀÀÁ¡
  • exclamation point hair
    °¨ÅººÎÈ£ÅÐ
  • focal point
    ÃÊÁ¡
  • freezing point
    ¾î´ÂÁ¡, ºùÁ¡
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mixed germ cell tumor
    È¥ÇÕ¹è¾Æ¼¼Æ÷Á¾¾ç
  • mixed lymphocyte reaction
    ¸²ÇÁ±¸È¥ÇÕ¹è¾ç¹ÝÀÀ
  • mixed lymphocyte culture test
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç°Ë»ç
  • mixed order reaction
    È¥ÇÕÂ÷¹ÝÀÀ
  • mixed suspended solid
    È¥ÇÕºÎÀ¯°íÇü¹°
  • dew point determination apparatus
    ³ëÁ¡°è
  • gingival point angle
    ÀÕ¸ö¸ð¼­¸®°¢
  • mesiobuccoocclusal point angle
    ¾ÈÂʺ¼Âʱ³ÇÕ¸éÁ¡°¢
  • mesiolinguaoocclusal point angle
    ¾ÈÂÊÇôÂʱ³ÇÕ¸éÁ¡°¢
  • boiling point
    ²ú´ÂÁ¡, ºñµîÁ¡
  • cardinal point
    ±âº»Á¡
  • conjugate point
    ÄÓ·¹Á¡, °áÇÕÁ¡
  • corresponding point
    ´ëÀÀÁ¡
  • craniometric point
    µÎ°³°èÃøÁ¡, ¸Ó¸®°èÃøÁ¡
  • critical point
    ÀÓ°èÁ¡
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • point counter
    ÷´Ü°è¼ö°ü(̧ËÀË­ËàË´).
  • point discharge
    Á¡¹æÀü.
  • point epidemic
    µ¹¿¬À¯Çà(ËôÌ´).
  • point estimation
    Á¡ÃßÁ¤¹ý(ËøÌ§ËøËÑ).
  • point mutation
    Á¡ µ¹¿¬º¯ÀÌ
  • point mutation
    Á¡µ¹¿¬º¯ÀÌ
  • point of basal convergence
    ±âÃÊÆøÁÖÁ¡(Ðñõ¨ÜßñÍïÇ).
  • point of condensation
    ÀÀÁýÁ¡(ëêó¢ïÇ).
  • point of convergence
    ÆøÁÖÁ¡(ÜßñÍïÇ).
  • point of fixation =p. of regard, fixa
    ÁÖ½ÃÁ¡(ñ¼ãÊïÇ).
  • point of maximal impulse
    ÃÖ´ë¹Úµ¿Á¡.
  • point of regard
    ÁÖ½ÃÁ¡.
  • point of symmetry
    ´ëĪÁ¡(ÓßöàïÇ).
  • point off axis
    ÃàÀÌÅ»ÁöÁ¡
  • point outside field
    Á¶»ç¿µ¿ª¹ÛÁöÁ¡
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mixed amputation
    È¥ÇÕ½ÄÀý´Ü(ûèùêãÒôîÓ¨).
  • mixed anesthesia
    È¥ÇÕ¸¶Ãë(¹ý)(¡­Ø«ö­Ûö).
  • mixed anxiety and depression
    È¥À缺 ºÒ¾È¿ì¿ïº´(ûèî¤àõ ÝÕäÌéØê¦Ü»)
  • mixed aphasia
    È¥ÇÕ¼º ½Ç¾îÁõ(¡­àõã÷åÞñø).
  • mixed aphasia
    È¥ÇÕ¼º ½Ç¾îÁõ(¡­àõã÷åÞñø).
  • mixed astigmatism
    È¥ÇÕ³­½Ã
  • mixed bacteria
    È¥ÇÕ¼¼±Õ
  • mixed base crude oil
    È¥ÇÕ±â¿øÀ¯(ûèùêÐñ ê«êú).
  • mixed beam irradiation
    È¥ÇÕºö¹æ»ç¼±Á¶»ç
  • mixed breech presentation
    º¹µÐÀ§ (ÜÙÔëêÈ).
  • mixed cellular cast
    È¥ÇÕ¼¼Æ÷¿øÁÖ
  • mixed chancre
    È¥ÇÕ¼º Çϰ¨
  • mixed color
    È¥ÇÕ»ö(ûèùêßä).
  • mixed connective tissue disease
    È¥ÇÕ °áÇÕÁ¶Á÷º´
  • mixed connective tissue disease
    È¥ÇÕ¼º °áüÁ¶Á÷ Áúȯ(¡­ Ì¿ô÷ðÚòÄ òðü´)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • end point
    Á¾¸»Á¡(ðûØÇïÇ)
  • end-point method
    Á¾¸»Á¡¹ý(ðûØÇïÇÛö)
  • end-point mutation
    Á¾¸»Á¡ º¯ÀÌ (ðûØÇïÇܨì¶)
  • equivalence point
    ´ç·®Á¡(Ó×ÕáïÇ)
  • extinction point
    ¼Ò¸êÁ¡(á¼ØþïÇ)
  • freezing-point osmometer
    ¾î´ÂÁ¡ »ïÅõ°è(ß¶÷âͪ)
  • growing point
    ¼ºÀåÁ¡(à÷íþïÇ)
  • hinge point
    µ¹Â¼±Í Á¡(ïÃ)
  • initiation point
    °³½ÃÁ¡(ËÒã·ïÇ)
  • isoelectric point
    µîÀüÁ¡(Ôõï³ïÇ)
  • isoelectrophoretic point
    µîÀü Àü±â¿µµ¿Á¡(Ôõï³ï³Ñ¨ç¶ÔÑïÇ)
  • isoionic point
    µî(Ôõ)À̿ Á¡(ïÇ)
  • isoprotic point
    µî¾çÀÚ Á¡(ÔõåÕí­ïÇ)
  • isosbestic point
    µîÈí±¤Á¡(ÔõýåÎÃïÇ)
  • light compensation point
    ±¤ º¸»óÁ¡(ÎÃÜÍßÁïÃ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
Sa the most anterior point of the anterior contour of the sella turcica [point]; saline; Staphylococcus...
Si the most anterior point on the lower contour of the sella turcica [point]; silicon
TP temperature and pressure; temperature probe; temporal peak; temporoparietal; tension pneumothorax; t...
DMH Daily Mixed Headache
DMLH Diffuse Mixed Lymphocytic Histiocytic
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PRESS Point resolved spectroscopy
RIP Repeat Induced Point mutation
tsp Transcription start point
tsp Transcriptional start point
2-PD Two-point discrimination
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • monogerminal mixed tumor
    ´Ü ¹è¿±¼º È¥ÇÕ Á¾¾ç
  • odontogenic mixed tumor
    Ä¡¿ø È¥ÇÕ Á¾¾ç
  • active myofascial trigger point
    Ȱµ¿¼º ±Ù¸· ¹ßÅëÁ¡
    ÃËÁøÀ» ÅëÇØ ÀÚ±ØÀ» ÁÖÁö ¾Ê´õ¶óµµ ±¹¼ÒÀûÀ̰ųª ÀüÀÌµÈ ÅëÁõÀ̳ª Áõ»óÀ» ³ªÅ¸³»´Â ±Ù¸· ¹ßÅëÁ¡.
  • arrow point tracer
    ¹¦±âÀåÄ¡
  • Barker's point
    ¹Ù¾ÆÄ¿ Á¡
    ¿ÜÀ̵µÀÇ Áß¾ÓÀÇ µÚÂÊ 1.25 ÀÎÄ¡, À§ÂÊ 1.25 ÀÎÄ¡ÀÎ Á¡.
  • boiling point
    ºñÁ¡, ºñµîÁ¡, ²ú´Â Á¡
  • breaking point
    ÆÄ´ÜÁ¡
  • central bearing point
    Á᫐ ÁöÁöÁ¡
    Áß¾Ó ÁöÁö ÀåÄ¡ÀÇ Á¢ÃËÁ¡.
  • central point artifact
    Áß½ÉÁ¡ Àΰø¹°
  • conjugate point
    °ø¾× Á¡, ÄÓ·¹ Á¡, °áÇÕ Á¡
  • cutaneous trigger point
    ÇǺΠ¹ßÅëÁ¡
  • dew point
    ³ëÁ¡
  • distal point therapy
    ¿øµµ ÃëÇ÷ ¿ä¹ý
  • equivalence point
    ´ç·® Á¡
  • fixed point
    °íÁ¤Á¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
mixed infection Infection by more than one variety of pathogenic microorganisms.
(05 Mar 2000)
mixed lymphocyte culture <investigation> Test to determine whether a patients and donor's white blood cells interact adversely. Often used to determine whether a person would be a suitable bone marrow donor for a particular patient.
(16 Dec 1997)
mixed lymphocyte culture test Measure of histocompatibility at the hl-a locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way mlc test, the lymphocytes from one of the individuals are inactivated (usually by treatment with mitomycin c or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens.
(12 Dec 1998)
mixed lymphocyte reaction <haematology, immunology, investigation> Reaction of mitogenesis produced in T lymphocytes when allogeneic (i.e. Mixed) lymphocytes are brought together, provided they are mismatched in histocompatibility loci. Once used as a test for possible graft compatibility in human grafting. Now known that a negative reaction is a poor predictor of graft acceptance.
(18 Nov 1997)
mixed mesodermal tumour A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells.
Synonym: malignant mixed mullerian tumour.
(05 Mar 2000)
mixed nerve <anatomy, nerve> A nerve containing both afferent and efferent fibres.
(05 Mar 2000)
mixed opioid agonist-antagonist <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type.
(13 Nov 1997)
mixed paralysis Combined motor and sensory paralysis.
(05 Mar 2000)
mixed sleep apnoea <chest medicine> A form of sleep apnoea where there is exists a combination of obstructive and central sleep apnoea syndromes.
(13 Nov 1997)
mixed thrombus A laminated thrombus, the layers of different ages being of different colour or consistency.
Synonym: stratified thrombus.
(05 Mar 2000)
mixed tide <ecology, marine biology> Tidal cycle in which there are usually two high and two low tides during a day.
(13 Nov 1997)
mixed tumour A tumour composed of two or more varieties of tissue.
(05 Mar 2000)
mixed tumour, malignant A malignant tumour composed of more than one type of neoplastic tissue.
(12 Dec 1998)
mixed tumour, mesodermal A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells. It is associated with previous pelvic radiation exposure in 20% of patients.
(12 Dec 1998)
mixed tumour, mullerian A tumour, basically a carcinoma with a single sarcoma such as leiomyosarcoma or angiosarcoma or multiple sarcomas of uterine origin. The role of oestrogen has been postulated as a possible aetiological factor in this tumour. (holland et al., cancer medicine, 3d ed, p1703)
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Point Four
    Á¦4Á¤Ã¥(Truman ´ëÅë·ÉÀÇ ¹Ì°³¹ß Áö¿ª °æÁ¦ ¿øÁ¶ Á¤Ã¥)
  • ball point pen
    º¼Ææ
  • black point
    Èæ¼öº´
  • boiling point
    ºñµîÁ¡
  • bradkeven point
    ä»êÁ¡
  • burning point
    ¹ßÈ­Á¡
  • cover point
    ÈÄÀ§
  • critical point
    ÀÓ°èÁ¡
  • dead point
    =DEAD CENTER
  • decimal point
    ¼Ò¼öÁ¡
  • dew point
    (±â»ó)(¿ÂµµÀÇ)À̽½Á¡;³ëÁ¡
  • dropoff point
    ¹è´Þǰ Àü´Þ Àå¼Ò;(À¯±« »ç°Ç µî¿¡¼­)¸ö°ªÀ» µÎ°í °¡´Â Àå¼Ò
  • end point
    Á¾·áÁ¡;Á¾Á¡;(È­)(ÀûÁ¤ÀÇ)Á¾Á¡;=ENDPOINT
  • equinoctial point
    (õ)ºÐÁ¡;ÁÖ¾ß ÆòºÐÁ¡
  • equitime point
    ÇൿÇѰèÁ¡;ÁøÃâ ÇѰèÁ¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á